Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure

European Journal of Health Economics

Volumn 11, Issue 1, 2010, Pages 95-104

  Merkesdal, Sonja ^a   Kirchhoff, Timm ^a   Wolka, Diane ^b   Ladinek, Gunter ^b   Kielhorn, Adrian ^c   Rubbert Roth, Andrea ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b ROCHE INNOVATION CENTER MUNICH   (Germany)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cost effectiveness; Rheumatoid arthritis; Rituximab; TNF failure; Tumour necrosis factor alpha inhibitor

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; ETANERCEPT; INFLIXIMAB; METHOTREXATE; RITUXIMAB;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG TREATMENT FAILURE; FEMALE; GERMANY; GOLD THERAPY; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; FEMALE; GERMANY; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMETRIC; PROBABILITY; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT FAILURE;

EID: 76649135795     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-009-0205-y     Document Type: Article

References (39)

1. J Smolen D Aletaha 2008 The burden of rheumatoid arthritis and access to treatment: a medical overview Eur. J. Health Econ. 8 Suppl 2 S39 S47 10.1007/s10198-007-0087-9
2. G Kobelt B Jönsson 2008 The burden of rheumatoid arthritis and access to treatment: outcome and cost-utility of treatments Eur. J. Health Econ. 8 Suppl 2 95 106 10.1007/s10198-007-0091-0
3. G Kobelt AS Woronoff B Richard P Peeters J Sany 2008 Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR study Joint Bone Spine 75 4 408 415 10.1016/j.jbspin.2007.07.015
4. T Pincus A Kavanaugh T Sokka 2004 Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies Clin. Exp. Rheumatol. 22 suppl 35 S2 S11
5. A Kavanaugh S Cohen J Cush 2004 The evolving use of tumour necrosis factor inhibitors in rheumatoid arthritis J. Rheumatol. 31 1881 1884
6. A Kavanaugh 2007 Economic consequences of established rheumatoid arthritis and its treatment Best Pract. Res. Clin. Rheumatol. 21 929 942 10.1016/j.berh.2007.05.005 (Pubitemid 47377807)
7. J Wong 2004 Cost-effectiveness of anti-tumor necrosis factor agents Clin. Exp. Rheumatol. 22 suppl 35 S65 S70
8. D Solomon A Maetzel 2004 Pharmacoeconomics of prescribing for rheumatoid arthritis Int. J. Adv. Rheumatol. 2 91 96
9. JC Edwards L Szczepanski J Szechinski A Filipowicz-Sosnowska P Emery DR Close, et al. 2004 Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis New Engl. J. Med. 350 2572 2581 10.1056/NEJMoa032534 (Pubitemid 38758544)
10. P Emery R Fleischmann A Filipowicz-Sosnowska J Schechtman L Szczepanski A Kavanaugh, et al. 2006 The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial Arthritis Rheum. 54 1390 1400 10.1002/art.21778
11. SB Cohen P Emery MW Greenwald M Dougados RA Furie MC Genovese, et al. 2006 Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum. 54 2793 2806 10.1002/art.22025 (Pubitemid 44497758)
12. Manger, B., Michels, H., Nüsslein, H.G., Schneider, M., Sieper, J.: Komission Pharmakotherapie der deutschen Gesellschaft für Rheumatologie. Neufassung der Empfehlungen der Deutschen Gesellschaft für Rheumatologie zur Therapie mit Tumornekrosefaktor-hemmenden Wirkstoffen bei entzündlich-rheumatischen Erkrankungen (03/2006)
13. A Kielhorn D Porter A Diamantopulos G Lewis 2008 Cost-utility analysis for the UK of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic DMARD Curr. Med. Res. Opin. 24 2639 2650 10.1185/03007990802321683
14. Sculpher, M., Claxton, K., Brazier, J., Jönsson, B.: Nice guidelines for economic evaluation: methodological developments and remaining uncertainties. European conference on health economics 2004, London
15. Data on file reported to Roche by Zink A et al. 2004
16. E Keystone R Fleischmann P Emery A Chubick M Duogados AR Baldassare, et al. 2007 Repeated treatment courses of rituximab in rheumatoid arthritis: sustained efficacy in patients with an inadequate response to one or more TNF inhibitors Ann. Rheum. Dis. 66 Suppl II 432
17. P Emery DE Furst G Ferraccioli J Udell RF van Vollenhoven K Rowe, et al. 2007 Sustained efficacy of repeat treatment courses of rituximab in rheumatoid arthritis patients with an inadequate response to disease-modifying anti-rheumatic drugs Ann. Rheum. Dis. 66 Suppl II 430
18. C Lajas L Abasolo B Bellajdel C Hernandez-Garcia L Carmona E Vargas, et al. 2003 Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study Arthritis Rheum. 49 64 70 10.1002/art.10905
19. K Michaud J Messer HK Choi F Wolfe 2003 Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7, 527 patients Arthritis Rheum. 48 2750 2762 10.1002/art.11439 (Pubitemid 37280602)
20. KM Pugner DI Scott JW Holmes K Hieke 2000 The costs of rheumatoid arthritis: an international long-term view Semin. Arthritis Rheum. 29 305 320 10.1016/S0049-0172(00)80017-7
21. E Yelin LA Wanke 1999 An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline Arthritis Rheum. 42 1209 1218 10.1002/1529-0131(199906)42:6<1209:: AID-ANR18>3.0.CO;2-M (Pubitemid 29268958)
22. Weinblatt, M.E., Kremer, J.M., Bankhurst, A.D., Bulpitt, K.J., Fleischmann, R.M., Fox, R.I., Jackson, C.G. et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor-FC fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New Engl. J. Med. 340; 253-259 (1999)
23. EC Keystone AF Kavanaugh JT Sharp H Tannenbaum Y Hua LS Teoh, et al. 2004 Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy Arthritis Rheum. 50 1400 1411 10.1002/art.20217 (Pubitemid 38608061)
24. MC Genovese JC Becker M Schiff M Luggen Y Sherrer J Kremer C Birbara J Box K Natarajan I Nuamah T Li T Aranda DT Hagerty M Dougados 2005 Abatacept for rheumatoid arthritis refractory to tumour necrosis factor alpha inhibition New Engl. J. Med. 353 1114 1123 10.1056/NEJMoa050524 (Pubitemid 41317434)
25. R Maini EW St Clair F Breedveld D Furst J Kalden M Weisman, et al. 1999 Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial Lancet 354 1932 1939 10.1016/S0140-6736(99)05246-0
26. N Bansback A Brennan O Ghatnekar 2005 Cost-effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Ann. Rheum. Dis. 64 995 1002 10.1136/ard.2004.027565 (Pubitemid 40909512)
27. DL Scott T Garood 2000 Quality of life measures: use and abuse Baillieres Clin. Rheumatol. 14 663 687 10.1053/berh.2000.0106 (Pubitemid 32010912)
28. AH Briggs BJ O'Brien G Blackhouse 2002 Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies Annu. Rev. Public. Health 23 377 401 10.1146/annurev.publhealth.23. 100901.140534 (Pubitemid 34508080)
29. BJ O'Brien AH Briggs 2002 Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods Stat. Methods Med. Res. 11 455 468 10.1191/0962280202sm304ra (Pubitemid 36096865)
30. A Finckh A Ciurea L Brulhart D Kyburz B Moller S Dehler, et al. 2007 B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents Arthritis Rheum. 56 1417 1423 10.1002/art.22520 (Pubitemid 46764068)
31. P Lindgren P Geborek G Kobelt 2009 Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from southern Sweden Int. J. Technol. Assess. Health Care 25 181 189 10.1017/S0266462309090230
32. A Russell A Beresniak L Bessette B Haraoui P Rahman C Thorne R Maclean D Dupont 2009 Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis Clin. Rheumatol. 28 403 412 10.1007/s10067-008-1060-4
33. A Brennan N Bansback R Nixon J Madan M Harrison K Watson D Symmons 2007 Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry Rheumatology 46 1345 1354 10.1093/rheumatology/kem115 (Pubitemid 47244512)
34. M Vera-Llonch E Massarotti F Wolfe N Shadick R Westhovens O Sofrygin R Maclean T Li G Oster 2008 Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumour necrosis factor-alpha antagonists J. Rheumatol. 35 1745 1753
35. Glenny, A., Altman, D., Song, F., Sakarovitch, C., Deeks, J., D'Amico, R. et al.: Indirect comparisons of competing interventions. Health Technol. Assess. 2005;9(26)
36. JB Wong G Singh A Kavanaugh 2002 Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis Am. J. Med. 113 400 408 10.1016/S0002-9343(02)01243-3 (Pubitemid 35223612)
37. G Kobelt L Jönsson A Young K Eberhardt 2003 The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study Rheumatology 42 326 335 10.1093/rheumatology/keg107 (Pubitemid 36305621)
38. Hurst, S., Platen, E., Rachev, S.: Subordinated market index models: a comparison. In: Miura R (ed) Asia-Pacific financial markets, vol 4(2). Springer, Berlin, pp. 97-124
39. G Kobelt K Eberhardt L Jönsson B Jönsson 1999 Economic consequences of the progression of rheumatoid arthritis in Sweden Arthritis Rheum. 42 347 356 10.1002/1529-0131(199902)42:2<347::AID-ANR18>3.0.CO;2-P (Pubitemid 29072853)